At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
NTRB Nutriband Inc.
Market Closed 12-12 16:00:00 EST
5.10
+0.13
+2.62%
盘后5.10
+0.000.00%
16:04 EST
High5.38Low4.89Vol10.75K
Open4.95D1 Closing4.97Amplitude9.86%
Mkt Cap62.00MTradable Cap19.87MTotal Shares12.16M
T/O53.95KT/O Rate0.28%Tradable Shares3.90M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Nutriband Inc. to Present at Noble Capital Markets Emerging Growth Equity Conference
Reuters  ·  11-24
Nutriband Inc. to Present at Noble Capital Markets Emerging Growth Equity Conference
Nutriband Inc - Meets With FDA for Aversa Fentanyl Feedback
THOMSON REUTERS  ·  10-28
Nutriband Inc - Meets With FDA for Aversa Fentanyl Feedback
Nutriband announces meeting completed with U.S. FDA for AVERSA FENTANYL
TIPRANKS  ·  10-28
Nutriband announces meeting completed with U.S. FDA for AVERSA FENTANYL
Nutriband Announces Successful Meeting Completed With United States FDA For Its Abuse Deterrent Fentanyl Patch
GlobeNewswire  ·  10-28
Nutriband Announces Successful Meeting Completed With United States FDA For Its Abuse Deterrent Fentanyl Patch
Press Release: Nutriband Co-Founder Gareth Sheridan Returns as CEO
Dow Jones  ·  10-27
Press Release: Nutriband Co-Founder Gareth Sheridan Returns as CEO
Nutriband (NTRB) Receives a Buy from Noble Financial
TIPRANKS  ·  10-23
Nutriband (NTRB) Receives a Buy from Noble Financial
Nutriband Signs Agreement With Brand Institute to Develop the Commercial Brand Name for Its Abuse Deterrent Fentanyl Patch
THOMSON REUTERS  ·  10-10
Nutriband Signs Agreement With Brand Institute to Develop the Commercial Brand Name for Its Abuse Deterrent Fentanyl Patch
Nutriband Inc signs agreement with Brand Institute to develop commercial brand name for abuse deterrent fentanyl patch
Reuters  ·  10-10
Nutriband Inc signs agreement with Brand Institute to develop commercial brand name for abuse deterrent fentanyl patch
Nutriband files provisional patent application for AVERSA technology
TIPRANKS  ·  10-08
Nutriband files provisional patent application for AVERSA technology
Nutriband Inc - Files Provisional Patent Application With Uspto for Aversa Technology
THOMSON REUTERS  ·  10-08
Nutriband Inc - Files Provisional Patent Application With Uspto for Aversa Technology
Nutriband Files Provisional Patent Application for Enhanced Transdermal Abuse Deterrent Technology
GlobeNewswire  ·  10-08
Nutriband Files Provisional Patent Application for Enhanced Transdermal Abuse Deterrent Technology
Nutriband To Present at the Noble Capital Markets’ Emerging Growth Virtual Equity Conference
GlobeNewswire  ·  10-08
Nutriband To Present at the Noble Capital Markets’ Emerging Growth Virtual Equity Conference
Nutriband Inc. to Present at MicroCap Rodeo Conference in New York City
Reuters  ·  09-25
Nutriband Inc. to Present at MicroCap Rodeo Conference in New York City
Investors bid Nutriband (NASDAQ:NTRB) up US$16m despite increasing losses YoY, taking three-year CAGR to 18%
Simply Wall St.  ·  09-16
Investors bid Nutriband (NASDAQ:NTRB) up US$16m despite increasing losses YoY, taking three-year CAGR to 18%
Nutriband Inc. Reports Q2 2026 Revenue of $0.6M, Highlighting 50% YoY Growth in Contract Manufacturing Sales
Reuters  ·  09-12
Nutriband Inc. Reports Q2 2026 Revenue of $0.6M, Highlighting 50% YoY Growth in Contract Manufacturing Sales
Noble Financial Sticks to Its Buy Rating for Nutriband (NTRB)
TIPRANKS  ·  09-12
Noble Financial Sticks to Its Buy Rating for Nutriband (NTRB)
Nutriband Q2 Adj. EPS $(0.18) Misses $(0.17) Estimate, Sales $622.452K Miss $705.000K Estimate
Benzinga  ·  09-10
Nutriband Q2 Adj. EPS $(0.18) Misses $(0.17) Estimate, Sales $622.452K Miss $705.000K Estimate
Nutriband Inc. Reports Q2 2025 Revenue Increase of 50.87% YOY, Strong Cash Position Supports AVERSA Fentanyl Development
Reuters  ·  09-10
Nutriband Inc. Reports Q2 2025 Revenue Increase of 50.87% YOY, Strong Cash Position Supports AVERSA Fentanyl Development
Press Release: Nutriband Inc. announces exercise of warrants at $6.43 for Gross Proceeds of $5,306,000
Dow Jones  ·  09-04
Press Release: Nutriband Inc. announces exercise of warrants at $6.43 for Gross Proceeds of $5,306,000
Nutriband Inc expected to post a loss of 17 cents a share - Earnings Preview
Reuters  ·  08-30
Nutriband Inc expected to post a loss of 17 cents a share - Earnings Preview

Introduction

Company Name.
Nutriband Inc.
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
Nutriband Inc. develops a portfolio of transdermal pharmaceutical products. The company's lead product in development is AVERSA fentanyl, an abuse deterrent fentanyl transdermal system that provides clinicians and patients with an extended-release transdermal fentanyl product for use in managing chronic pain requiring around the clock opioid therapy. It also develops AVERSA buprenorphine and AVERSA methylphenidate, and other transdermal pharmaceutical products. The company was incorporated in 2016 and is headquartered in Orlando, Florida.
Issue price:
--